Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic
syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia
induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of
uric acid with febuxostat it is hypothesized that the levels of oxidative stress in adipose
tissue (obtained by fat biopsy) will decrease.
Primary aims of the study are to determine whether febuxostat therapy in overweight or obese,
diabetic patients with stage 3 Chronic Kidney Disease (CKD) and high serum uric acid levels
1. will affect adipose tissue concentrations of thiobarbituric acid reactive substance
(TBARS), a marker of oxidative stress
2. will affect adipose tissue expression and concentrations of adiponectin; and
3. will affect urinary concentrations of transforming growth factor (TGF)- B1.